Farletuzumab
Modify Date: 2024-04-02 20:27:13
Farletuzumab structure
|
Common Name | Farletuzumab | ||
|---|---|---|---|---|
| CAS Number | 896723-44-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of FarletuzumabFarletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a therapeutic humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer[1]. |
| Name | Farletuzumab |
|---|
| Description | Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a therapeutic humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Farletuzumab (MORAb-003; 0-10 µg/mL; CHO-FR cells) inhibits FRα-dependent cell growth and increases folate EC50 in a dose-dependent manner[1]. Farletuzumab (0.1-100 µg/mL; IGROV-1 cells; 1 h) mediates tumor cytotoxicity via complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro[1]. Farletuzumab (0-10 µg/mL; CHO-FR cells) inhibits phosphorylation of proteins by Lyn kinase, a member of the src family of kinases, thereby, blocking a FRa-mediated signaling pathway[1]. Cell Cytotoxicity Assay[1] Cell Line: IGROV-1 cells Concentration: 0.1, 1, 10, and 100 µg/mL Incubation Time: 1 hours Result: Had significant cytotoxicity at IGROV-1 cells. |
| References |
| No Any Chemical & Physical Properties |